Investing in a new generation
of portable immunological analysis.
A technological response
to a medical, economic and operational need.
Essential analyses,
but still too constrained.
One drop of blood, under 30 minutes.
A more accessible model.
A platform designed
for several high-potential markets.
Neonatology, pediatrics, critical care, and hospitals represent the core of the Preciphos strategy—areas where rapid access to selected biological data can have a meaningful impact on healthcare organization and patient management.
Medical research, client test transfer, and biomarker monitoring—an application area already supported by active early-stage clients.
Livestock, companion animals, and rapid diagnostics delivered closer to the veterinary point of care.
Field applications, specialized monitoring, and chemical detection, building upon the core technological platform.
A recurring model
based on analyzers and consumables.
A trajectory already underway.
A clear trajectory
towards commercialization and international expansion.
Growth potential
driven by analyzer deployment.
The growth trajectory is based on the progressive deployment of analyzers and the expansion of recurring revenue generated by consumables. The figures presented below reflect Preciphos’s Total Addressable Market (TAM) potential and long-term scenario, and should not be interpreted as current revenue or guaranteed future performance.
Pre-Series A: accelerating validation, industrialization and deployment.
An experienced team to drive an ambitious medtech platform.
Preciphos brings together a leadership team and an advisory board combining scientific, medical, technical, financial, and international business development expertise.
Chief Executive Officer — 40 years of experience in business development.
Chief Medical Development Officer — 29 years of experience in medical research.
Chief Financial Officer, Co-Founder — 20 years of experience in finance and controlling.
Additional documents
in a private area.
Detailed investor materials are available within a private area, accessible to qualified stakeholders. These include the Executive Summary, One-Pager, and other resources approved by Preciphos according to the level and context of the discussion.
Executive Summary, One-Pager, and strategic resources intended for specialized investors seeking to evaluate the medtech opportunity.
Access is granted following stakeholder qualification.
Let’s discuss your interest so we can provide the resources best suited to your level of analysis and investment evaluation.
Would you like to assess
the Preciphos opportunity?
Preciphos offers qualified discussions with investors who would like to gain a deeper understanding of the FoRe technology, business model, roadmap, target markets, and long-term growth potential.